BIOMAT Database Logo BIOMAT Database Logo

Tumor-infiltrating lymphocytes and interleukin-2 in melanomas. 1989

P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
June 1986, Cancer research,
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Oligoclonality of tumor-infiltrating lymphocytes from human melanomas.
September 1994, Journal of immunology (Baltimore, Md. : 1950),
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas.
May 1989, Journal of immunology (Baltimore, Md. : 1950),
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.
January 2000, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.
October 2016, Melanoma research,
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes.
January 1990, Biotherapy (Dordrecht, Netherlands),
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Metabolism of peripheral lymphocytes, interleukin-2-activated lymphocytes and tumor-infiltrating lymphocytes from 31P NMR studies.
November 1989, FEBS letters,
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.
November 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Autoimmune Addison's disease after treatment with interleukin-2 and tumor-infiltrating lymphocytes.
January 1995, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
P M Sondel, and J A Sosman, and J A Hank, and P C Kohler, and B Storer
Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.
January 2019, Oncoimmunology,
Copied contents to your clipboard!